Lymphoma  >>  Gazyva (obinutuzumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

138 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT00576758 / 2008-003460-19: GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Checkmark BSH 2015
Apr 2015 - Apr 2015: BSH 2015
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Checkmark P2 data
More
Completed
2
175
US, Canada, Europe, RoW
obinutuzumab (RO5072759), RO5072759, GA101, GAZYVA®, rituximab
Hoffmann-La Roche
Non-Hodgkin's Lymphoma
09/11
03/13
NCT01414205: A Study Comparing Obinutuzumab (RO5072759; GA101) 1000 Milligram (mg) Versus 2000 mg in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GAGE)

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark For CLL
Jun 2013 - Jun 2013: For CLL
Completed
2
80
US
Obinutuzumab, RO5072759; GA101, Corticosteroids
Genentech, Inc.
Lymphocytic Leukemia, Chronic
03/13
03/16
NCT00517530 / 2007-001103-37: A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

Checkmark B-cell non-Hodgkin lymphoma
Dec 2015 - Dec 2015: B-cell non-Hodgkin lymphoma
Checkmark Indolent non-Hodgkin lymphoma
Jul 2013 - Jul 2013: Indolent non-Hodgkin lymphoma
Checkmark relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma
More
Completed
2
134
Europe
Obinutuzumab, RO5072759, GA101
Hoffmann-La Roche
Lymphoma
11/13
11/13
GATHER, NCT01414855: A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma

Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Checkmark ASH 2013
Nov 2013 - Nov 2013: ASH 2013
Completed
2
100
US
obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Genentech, Inc.
Lymphoma, B-Cell
12/13
12/16
NCT01868893: An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Checkmark Presentation of data for stage II CLL11 trial at ASH 2013
Dec 2013 - Dec 2013: Presentation of data for stage II CLL11 trial at ASH 2013
Completed
2
20
US
Obinutuzumab, RO 5072759, GA101, Chlorambucil
Genentech, Inc.
Chronic Lymphocytic Leukemia
01/14
01/14
2013-004635-69: A phase II study of obinutuzumab monotherapy in rituximab-refractory follicular lymphoma Obinutuzumab monotherapie voor rituximab-refractair folliculair lymfoom

Ongoing
2
25
Europe
obinutuzumab, obinutuzumab-N-succinyl-desferal-zirconium-89, RO5072759, 89Zr-obinutuzumab, Concentrate for solution for infusion, Solution for injection/infusion
VU University Medical Center, VU University Medical Center, Roche Nederland B.V.
rituximab refractory follicular lymphoma, rituximab refractory follicular lymphoma, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B.

Not yet recruiting
2
90
Europe
Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag
Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01889797: Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

Terminated
2
32
US
Arm A: Rituximab, IDEC-C2B8, Chimeric anti-CD20 monoclonal antibody, Rituxan, NSC# 687451, Arm B: GA101, Obinutuzumab, RO5072759, huMAB
PrECOG, LLC., Genentech, Inc.
Indolent Non-Hodgkin's Lymphoma
04/16
08/16
NCT02420210: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Terminated
2
2
US
Bendamustine Hydrochloride, Ribomustin, SyB L-0501, Treanda, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759, Dexamethasone, DM, Quality-of-Life Assessment, Quality of Life Assessment, Laboratory Biomarker Analysis
University of Chicago, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma
08/16
08/16
2016-001033-27: REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia (MW) REMODEL - WM3 Etude ouverte de phase II évaluant l’efficacité d’un traitement «sans chimiothérapie » par l’association de l’Idelalisib avec l’Obinutuzumab chez les patients atteints de la Maladie de Waldenström (MW)

Ongoing
2
50
Europe
Obinutuzumab, R05072759/F06-01, Concentrate for solution for infusion, Film-coated tablet, Gazyvaro, Zydelig
FILO, Roche, GILEAD
Waldenstrom’s Macroglobulinemia (MW) Macroglobulinémie de Waldenstrom (MW), Patient with relapsed/refractory Waldenstrom’s Macroglobulinemia Patient en rechute ou réfractaire d'une macroglobulinémie de Waldenstrom, Diseases [C] - Cancer [C04]
 
 
2015-004985-27: A prospective, open-label, multicenter randomized phase-II trial to evaluate the efficacy and safety of a sequential regimen of obinutuzumab (Gazyvaro) followed by obinutuzumab and venetoclax, followed by either standard venetoclax maintenance or MRD guided venetoclax maintenance in first-line patients with CLL and unfit for FCR-like regimens

Ongoing
2
70
Europe
obinutuzumab, venetoclax 10 mg, venetoclax 50mg, venetoclax 100mg, Concentrate for solution for infusion, Tablet, Gazyvaro
HOVON Foundation, Dutch Cancer Society, Roche
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
GIBB, NCT02320487: A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Completed
2
102
US
Bendamustine, Treanda, Levact, Obinutuzumab, GA101, Gazyva™, RO5072759
Genentech, Inc.
Chronic Lymphocytic Leukemia
11/16
02/19
FIL-GALILEO, NCT02670317: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Terminated
2
1
Europe
Obinutuzumab, GA101, Ibrutinib, Imbruvica, CHOP, Cyclophosphamide, doxorubicin, vincristine, and prednisone, Hydroxydaunomycin, Oncovin
Fondazione Italiana Linfomi ONLUS
Lymphoma, B-Cell
02/17
02/17
ROMULUS, NCT01691898 / 2011-004377-84: A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Checkmark ROMULUS trial of polatuzumab + Gazyva/Rituxan for r/r FL and DLBCL at ASH 2016
Dec 2016 - Dec 2016: ROMULUS trial of polatuzumab + Gazyva/Rituxan for r/r FL and DLBCL at ASH 2016
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ROMULUS trial for NHL
More
Completed
2
231
Europe, Canada, US
Obinutuzumab, GA101, Gazyva, Gazyvaro, Pinatuzumab Vedotin, DCDT2980S, Polatuzumab Vedotin, DCDS4501A, Rituximab, MabThera/Rituxan
Genentech, Inc.
Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
03/17
02/19
FIL_GAEL, NCT02495454 / 2014-005697-10: GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma

Terminated
2
34
Europe
Ga101, Obinutuzumab
Fondazione Italiana Linfomi ONLUS
CD20 Positive Diffuse Large B-cell Lymphoma, Elderly Unfit Patients
03/17
03/17
ICLL-07, NCT02666898: Phase II Trial GA101 Inbrutinib B CLL

Completed
2
135
Europe
GA101, Obinutuzumab, Ibrutinib, Imbruvica, Cyclophosphamide, Endoxan, Fludarabine, Fludara
French Innovative Leukemia Organisation, Roche Pharma AG, Janssen-Cilag Ltd.
Leukemia, Lymphocytic, Chronic, B-Cell
05/17
03/18
2016-003579-22: A Study Exploring the Safety and Efficacy of Atezolizumab Administered in Combination with Obinutuzumab or Rituximab Anti-CD20 Therapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma and Waldenström Macroglobulinemia Estudio fase II de seguridad y eficacia de Atezolizumab administrado en combinación con terapia anti-CD20 Obinutuzumab o Rituximab en pacientes con linfoma de células del manto o de la zona marginal y macroglobulinemia de Waldenström refractarios o en recaída.

Completed
2
120
Europe
Atezolizumab, MabThera 500 mg concentrate for solution for infusion, MabThera 1400 mg solution for subcutaneous injection, RO5541267, RO0452294, Solution for infusion, , Solution for injection, Gazyvaro 1,000 mg, MabThera 500 mg concentrate for solution for infusion, MabThera 1400 mg solution for subcutaneous injection
Roche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche, F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F.Hoffman-La Roche Ltd.
Relapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM) LINFOMA DE CÉLULAS DEL MANTO, LINFOMA DE LA ZONA MARGINAL, MACROGLOBULINEMIA DE WALDENSTRÖM, MCL is a B-cell non-Hodgkin lymphoma (lymph nodes, spleen, etc); MZL (B-cell lymphoma) arise from post-germinal center marginal zone B-cell; WM is a lymphoplasmacytic lymphoma in the bone marrow. LCM linfoma no Hodgkin de células B (ganglios linfáticos, bazo, etc); LZM (linfoma de células B) zona marginal del centro post-germinal de células B; MW linfoma linfoplasmocitario en la médula ósea., Diseases [C] - Cancer [C04]
 
 
NCT02071225 / 2013-003388-79: A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Completed
2
72
Europe
bendamustine, obinutuzumab, RO5072759
Hoffmann-La Roche
Chronic Lymphocytic Leukemia
11/18
11/18
NCT02499003 / 2014-004780-21: GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

Completed
2
70
Europe
Obinutuzumab and Pixantrone, GA101 /Gazyvaro, Pixuvri
Johannes Gutenberg University Mainz, Roche Pharma AG, Servier
Lymphoma, Non-Hodgkin
01/19
01/22
NCT02983617 / 2016-002768-15: Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)

Completed
2
36
Europe
Tirabrutinib, GS-4059, ONO-4059, Entospletinib, GS-9973, Obinutuzumab, Gazyvaro®, Gazyva®, GA101
Gilead Sciences, German CLL Study Group
Chronic Lymphocytic Leukemia
02/19
10/20
LYMA-101, NCT02896582 / 2016-000548-33: Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

Checkmark From LyMa-101 trial in combination with high-dose cytarabine induction in 1L mantle cell lymphoma
Sep 2020 - Sep 2020: From LyMa-101 trial in combination with high-dose cytarabine induction in 1L mantle cell lymphoma
Active, not recruiting
2
86
Europe
Obinutuzumab, GA, GA101, Dexamethasone, Aracytine, Cytarabine, Cisplatinum, Etoposide, Melphalan, Carmustine, BiCNU, BCNU
The Lymphoma Academic Research Organisation
Mantle Cell Lymphoma
03/19
03/25
OBI-1, NCT03679455 / 2016-005053-20: A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia,

Recruiting
2
30
Europe
Obinutuzumab 25 MG/ML, Gazyvaro
Polish Myeloma Consortium, Roche Pharma AG, Bioscience, S.A.
Waldenstrom Macroglobulinemia
04/19
12/22
CLLTX1, NCT03153514 / 2015-000568-32: Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

Terminated
2
3
Europe
Obinutuzumab, GA-101, Gazyva
German CLL Study Group, Hoffmann-La Roche
Chronic Lymphocytic Leukemia, Richter's Transformation
05/19
06/19
2018-001229-18: Idelalisib (I) in combination with Obinutuzumab (G) for the treatment of patients with relapsed / refractory follicular lymphoma: multicentric phase II single arm study. Idelalisib (I) in combinazione con Obinutuzumab (G) per il trattamento di pazienti con linfoma follicolare ricaduto/refrattario: studio multicentrico di fase II a braccio singolo.

Not yet recruiting
2
43
Europe
Zydelig, GAZYVARO, [IMP1], [Obinutuzumab], Capsule, hard, Concentrate for solution for infusion, Zydelig, Gazyvaro
FONDAZIONE ITALIANA LINFOMI ONLUS, GILEAD, ROCHE
recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, recurrent / refractory follicular lymphoma linfoma follicolare ricaduto/refrattario, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02968563 / 2015-003909-42: Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Completed
2
35
Europe
Tirabrutinib, GS-4059, Idelalisib, Zydelig®, GS-1101, CAL-101, Obinutuzumab, Gazyvaro®, Gazyva®, GA101
Gilead Sciences, German CLL Study Group
Chronic Lymphocytic Leukemia
06/19
01/21
LYSA, NCT03276468 / 2016-005061-31: Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas

Completed
2
136
Europe
Atezolizumab, Tecentriq, Obinutuzumab, Gazyvaro, Venetoclax, Venclyxto
The Lymphoma Academic Research Organisation
Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue
09/19
08/22
NCT02371590: Lenalidomide and Obinutuzumab for Previously Untreated CLL

Withdrawn
2
0
US
Lenalidomide, Revlimid, Obinutuzumab, Gazyva
University of California, San Diego, Celgene Corporation, Genentech, Inc.
Chronic Lymphocytic Leukemia
12/19
12/22
OPERA PLRG-10, NCT03229382 / 2015-005439-41: Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

Terminated
2
1
Europe
Obinutuzumab, Gazyvaro, GA101
Polish Lymphoma Research Group, Roche Pharma AG
Mantle Cell Lymphoma
01/20
01/20
2018-003270-27: Evaluation of a treatment with bendamustine, followed by obinutuzumab,zanubrutinib and venetoclax in patients with relapsed chronic lymphocyticleukemia

Not yet recruiting
2
40
Europe
Bendamustine, Obinutuzumab / GA101, ABT-199 (GDC-0199), Venetoclax, Zanubrutinib, RO5072759, BGB-3111, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tablet, Capsule, hard, Gazyvaro, Venclyxto (Venetoclax)
Universität zu Köln B.1.2, BeiGene Ltd., Roche Pharma AG
Patients with relapsed/refractory CLL requiring treatment, Patients with relapsed chronic lymphocytic leukaemia in need oftreatment, Diseases [C] - Cancer [C04]
 
 
2018-004038-13: Chemotherapy-free combination of Copanlisib withObinutuzumab (GA 101) in Patients with Previously Untreated FollicularLymphoma (FL) and High Tumor Burden

Not yet recruiting
2
102
Europe
Copanlisib, Obinutuzumab, BAY 80-6946, RO5072759/F06-01, Lyophilisate for solution for infusion, Concentrate for solution for infusion, Gazyvaro
Klinikum der Universität München, Bayer HealthCare Pharmaceuticals Inc., Roche Pharma AG
Follicular Lymphoma with high tumor burden (grade 1- 3a, Ann Arbour stage II - IV, previously untreated), Follicular Lymphoma with need of treatment, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
RemodelWM3, NCT02962401: Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Completed
2
50
Europe
Obinutuzumab, GA101, Idelalisib, Zydelig
French Innovative Leukemia Organisation
Waldenstrom Macroglobulinemia
08/20
04/23
NCT02750670: Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Completed
2
30
Canada
Obinutuzumab, GAZYVA, Gemcitabine, Dexamethasone, Decadron, Cisplatin
University Health Network, Toronto, Hoffmann-La Roche, Ozmosis Research Inc.
Lymphoma, Non-Hodgkin's
09/20
02/21
NCT03755947: Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Completed
2
3
RoW
Ibrutinib, Imbruvica, Obinutuzumab, Gazyva, Venetoclax, Venclexta
Grupo Cooperativo de Hemopatías Malignas
B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
12/20
02/21
GAUDEALIS, NCT03890289: Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Terminated
2
5
Europe
Idelalisib, Obinutuzumab
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
04/21
05/23
NCT02225275: Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Terminated
2
9
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
05/21
05/21
NCT02736617: Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Completed
2
10
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
06/21
06/21
2021-000311-23: Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Ibrutinib e Obinutuzumab come trattamento di prima linea per pazienti affetti dalla Leucemia Linfatica Cronica

Not yet recruiting
2
53
Europe
NA, Gazyvaro, [NA], [Gazyvaro], Capsule, hard, Concentrate for solution for injection, imbruvica, gazyvaro
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, Diseases [C] - Cancer [C04]
 
 
NCT02987400 / 2016-001760-10: Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL

Completed
2
22
Europe
Venetoclax, GA-101, Obinutuzumab, Gazyvaro
Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG
Lymphoma, Large B-Cell, Diffuse
10/21
10/21
GAZAI, NCT03341520 / 2016-002059-89: Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma

Active, not recruiting
2
89
Europe
Obinutuzumab Injection [Gazyva], Gazyvaro, Low dose radiation Therapy (LDRT)
Heidelberg University, Roche Pharma AG
Stage II Grade 1 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma, Stage I Follicular Lymphoma Grade 1, Stage II Follicular Lymphoma Grade 2
11/21
05/24
GABe2016, NCT03492775 / 2016-000755-27: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years

Completed
2
46
Europe
Obinutuzumab, GA 101, Bendamustine, Bendamustine hydrochloride; Ribomustin
Prof. Dr. Wolfgang Hiddemann, Hoffmann-La Roche, Mundipharma Research GmbH & Co KG
Indolent Non-hodgkin Lymphoma
11/21
12/22
CLL2-GiVe, NCT02758665 / 2015-004606-41: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Checkmark From CLL2GIVe trial in combination with Imbruvica & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Jun 2020 - Jun 2020: From CLL2GIVe trial in combination with Imbruvica & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Checkmark From CLL2GIVe trial in combination with venetoclax & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Jun 2020 - Jun 2020: From CLL2GIVe trial in combination with venetoclax & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Completed
2
41
Europe
ibrutinib, obinutuzumab, venetoclax
University of Ulm, German CLL Study Group, Roche Pharma AG, Janssen-Cilag Ltd., AbbVie
Leukemia, Lymphocytic, Chronic
01/22
03/22
2019-000914-12: Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors

Not yet recruiting
2
27
Europe
TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab/, Infusion, Injection, TECENTRIQ (atezolizumab), GAZYVA (Obinutuzumab)
University of Cologne, F. Hoffmann La Roche
• Melanoma: unresectable stage III with macroscopic lymph node, in transit/satellite metastasis or stage IV after ≥ 2 lines of therapy (incl. checkpoint blockade, BRAF inhibitor)• Prostate carcinoma: castration-resistant, 2 lines of chemotherapy failed• CTCL: ≥ stage IIB, ≥ 2 previous lines of treatment, Patients with late stage Melanoma, Prostate carcinoma or Cutaneous T cell lymphoma (CTCL), Diseases [C] - Cancer [C04]
 
 
NCT02689869 / 2014-005164-15: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Active, not recruiting
2
98
Europe
Ibrutinib, Imbruvica, GA 101, Obinutuzumab
Ludwig-Maximilians - University of Munich, Hoffmann-La Roche, Janssen-Cilag G.m.b.H
Indolent Non-Hodgkin Lymphoma
04/22
07/22
ROSEWOOD, NCT03332017 / 2017-001552-54: A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

Active, not recruiting
2
217
Europe, Canada, US, RoW
Zanubrutinib, BGB-3111, Brukinsa, Obinutuzumab, Gazyva
BeiGene
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
10/21
10/24
NCT04059081: A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

Unknown status
2
31
RoW
Obinutuzumab
Deok-Hwan Yang, Roche Pharma AG
Chronic Lymphocytic Leukemia
07/22
07/22
Alternative-C, NCT05387616: A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden

Active, not recruiting
2
98
Europe
Copanlisib, ALIQOPA™, Obinutuzumab, GAZYVARO®
Ludwig-Maximilians - University of Munich, Roche Pharma AG, Bayer
Follicular Lymphoma
09/23
05/26
2022-002579-12: First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-2 inhibitor with BTK inhibitor according to disease status of the young patient with high risk Chronic Lymphatic Leukemia Associazione di un inibitore di Bcl-2 e un anticorpo monoclonale in prima linea seguita dalla somministrazione del solo inibitore di Bcl-2 o dall'associazione dell'inibitore di Bcl-2 con un inibitore di BTK in base all'andamento della malattia del paziente giovane con Leucemia linfatica cronica ad alto rischio.

Not yet recruiting
2
78
Europe
Gazyvaro 1000 mg, Venclyxto 10 mg, Venclyxto 50 mg, Venclyxto 100 mg, Brukinsa, Bactrim, Lamivudina, Trimeton, Tachipirina, Decadron, Allopurinolo, [NA], [N.A.], Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Tablet, Concentrate for solution for injection, Solution for injection, Buccal tablet
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus
Chronic Lymphocytic Leukemia Leucemia linfatica cronica, Form of cancer characterized by the abnormal proliferation of a particular type of cells present in the blood (lymphocytes) with consequent accumulation in various parts of the body Forma di cancro caratterizzata dalla proliferazione abnorme di un particolare tipo di cellule presenti nel sangue (linfociti) con conseguente accumulo in varie parti del corpo, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-003398-51: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dose R-CHOP Eine prospektive, multizentrische Phase-2-Studie zur chemotherapiearmen Kombination von Rituximab mit dem Antikörper-Wirkstoff-Konjugat Polatuzumab Vedotin und dem bispezifischen Antikörper Glofitamab bei zuvor unbehandelten Patienten mit aggressivem B-Zell-Lymphom über 60 Jahren, die für ein voll dosiertes R-CHOP nicht in Frage kommen

Not yet recruiting
2
80
Europe
Glofitamab, Obinutuzumab, Polatuzumab vedotin, Rituximab, RO7082859, RO5072759, RO5541077, RO0452294, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Columvi, GAZYVARO, Polivy, MabThera
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Roche Pharma AG, Roche Austria GmbH
aggressive large B-cell lymphoma, aggressive large B-cell lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT03311126: Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Terminated
2
21
US
Bendamustine, Obinutuzumab, GA101, RO5072759
University of Wisconsin, Madison, Genentech, Inc.
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma
07/23
07/23
NCT03872180: Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
23
US
Bendamustine, SDX-105, Obinutuzumab, GA-101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, RG7601, Venclexta, RO5537382
Emory University, Genentech, Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
CCND1 Positive, Mantle Cell Lymphoma, t(11;14) Positive
09/24
04/26
BiCAR, NCT04703686 / 2020-001985-12: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Active, not recruiting
2
67
Europe
Obinutuzumab, gazyva, RO7082859, glofitamab
The Lymphoma Academic Research Organisation
Diffuse Large B-Cell Lymphoma Refractory, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Cell Lymphoma, Refractory Mantle Cell Lymphoma
01/23
03/26
NCT04450173: Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Recruiting
2
40
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Joseph Tuscano, National Cancer Institute (NCI), Pharmacyclics LLC., Genentech, Inc.
Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
10/24
04/25
FLUORO, NCT04962126: Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy

Active, not recruiting
2
15
RoW
Obinutuzumab 25 MG/1 ML Intravenous Solution, Gazyva, Atezolizumab 1200 MG/40mL Intravenous Solution, Tecentriq, 4 Gy in 2 fractions
Olivia Newton-John Cancer Research Institute, Roche Products Pty Limited, Austin Health, Ballarat Health Services
Follicular Lymphoma
04/23
07/25
NCT06415708: Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Recruiting
2
134
RoW
Obinutuzumab Combined With Bendamustine
Institute of Hematology & Blood Diseases Hospital, China
B Cell Lymphoma
11/24
06/26
17P.176, NCT03198026: Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Recruiting
2
30
US
Ibrutinib, 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, 936563-96-1, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, Gazyva, R7159, RO 5072759, GA-101, GA101, huMAB(CD20), RO-5072759, RO5072759, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Genentech, Inc., Pharmacyclics LLC.
Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Nodal Marginal Zone Lymphoma, Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Nodal Marginal Zone Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Nodal Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Splenic Marginal Zone Lymphoma, Stage IV Splenic Marginal Zone Lymphoma
12/24
02/31
NCT05510219: Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China

Recruiting
2
200
RoW
intravenous rapid infusion of obinutuzumab
The First Affiliated Hospital with Nanjing Medical University
Obinutuzumab, Rapid Infusion, Intravenous Infusion Reaction
12/23
12/23
NCT05823701: Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Recruiting
2
23
RoW
Chidamide, Tucidinostat, Azacitidine, AZA, obinutuzumab, Gazyva, Liposomal mitoxantrone, PLM60
The First Affiliated Hospital of Soochow University
Diffuse Large B-Cell Lymphoma
12/23
12/25
NCT02498951: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Terminated
2
32
US
Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment
OHSU Knight Cancer Institute, Genentech, Inc., National Cancer Institute (NCI), Oregon Health and Science University, Providence Health & Services
Central Nervous System B-Cell Non-Hodgkin Lymphoma
03/24
03/24
NCT04883437: Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Recruiting
2
49
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Emory University, AstraZeneca, National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Lymphoproliferative Disorder, Mantle Cell Lymphoma, Marginal Zone Lymphoma
01/24
01/24
NCT03401853: Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma

Active, not recruiting
2
18
US
Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83, rituximab biosimilar TQB2303, rituximab-abbs, Truxima, Rituximab Biosimilar SIBP-02, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
University of Washington, Merck Sharp & Dohme LLC
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
12/23
12/25
NCT06175000: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Recruiting
2
30
US
Cognitive Assessment, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB (CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality of Life Assessment
Providence Health & Services
Primary Central Nervous System Lymphoma
09/28
09/29
NCT03580928: Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL

Hourglass Dec 2022 - Dec 2022 : Presentation of data from Phase 2 trial in combination with Venetoclax and Obinutuzumab for 1L CLL at ASH 2022
Active, not recruiting
2
72
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Dana-Farber Cancer Institute, AstraZeneca, Genentech, Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia (CLL)
04/24
12/27
NCT06333262: Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab
Inhye Ahn, Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/27
02/29
NCT06324994: Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Not yet recruiting
2
10
RoW
Linperlisib in combination with Obinutuzumab and Venetoclax, Treatment group
Dalian Medical University
Mantle Cell Lymphoma
05/25
12/26
NCI-2024-00054, NCT06252675: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Not yet recruiting
2
50
US
Obinutuzumab, Anti-CD20 Monoclonal Antibody R715, huMAB(CD20), RO5072759, Glofitamab, Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO7082859, Pirtobrutinib, LOXO-305, Tumor Imaging, FDG-PET, Computed Tomography (CT), Biospecimen Collection, Biological Sample Collection, ClonoSeq Assay, ClonoSeq, Bone Marrow Biopsy, Biopsy of Bone Marrow
C. Babis Andreadis, Eli Lilly and Company, Genentech, Inc., Adaptive Biotechnologies
Mantle Cell Lymphoma
03/28
03/28
NCI-2024-00209, NCT06213311: A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Recruiting
2
40
US
Glofitamab, RO7082859, RG6026, Obinutuzumab, GA101, Gazyva, RO5072759, Axi-cel, Axicabtagene ciloleucel, KTE-C19, KTE-X19
M.D. Anderson Cancer Center, Genentech, Inc., Kite, A Gilead Company
B Cell Lymphoma
01/25
01/27
NCT06427213: This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

Not yet recruiting
2
41
NA
Zanubrutinib,Obinutuzumab, Zanubrutinib and R-BAC
Henan Cancer Hospital
Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin
12/27
12/29
OLYMP-1, NCT03322865 / 2017-003149-56: Obinutuzumab in Marginal Zone Lymphoma

Active, not recruiting
2
56
Europe
Obinutuzumab, GA101
Christian Buske, University of Ulm, Optimapharm, Zentrum für Klinische Studien Ulm, X-act Cologne Clinical Research GmbH, Roche Pharma AG
Marginal Zone Lymphoma
06/24
11/28
NCT04505254: Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Recruiting
2
60
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/24
06/24
NCT06454968: Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Recruiting
2
45
RoW
Orelabrutinib, obinutuzumab, lenalidomide
Peking Union Medical College Hospital
Marginal Zone Lymphoma
06/26
06/28
SWOG S1608, NCT03269669: Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recruiting
2
95
US
Bendamustine Hydrochloride, Belrapzo, Bendamustin Hydrochloride, Bendeka, CEP-18083, Cytostasan Hydrochloride, Levact, Ribomustin, SyB L-0501, Treakisym, Treanda, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Echocardiography, EC, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Umbralisib, 2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one, RP-5264, RP5264, TGR-1202, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
12/25
12/25
NCT02871219: Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

Active, not recruiting
2
96
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Bulky Disease, Fatigue, Fever, Grade 3a Follicular Lymphoma, Night Sweats, Splenomegaly, Weight Loss
07/24
07/24
NCI-2021-12489, NCT05169658: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Recruiting
2
42
US
Mosunetuzumab, 1905409-39-3, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, RG 7828, RG-7828, RG7828, RO7030816, Lunsumio, Mosunetuzumab-axgb, Obinutuzumab, 949142-50-1, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Polatuzumab Vedotin, 1313206-42-6, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000
University of Washington, Genentech, Inc.
Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
12/25
12/25
O-ICE, NCT02393157: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting
2
25
US
Obinutuzumab, Gazyva, Liposomal ARA-C, Depocyte, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16
New York Medical College, Roswell Park Cancer Institute
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
12/24
12/24
UPCC 48420, NCT04889716: CAR-T Followed by Bispecific Antibodies

Recruiting
2
42
US
mosunetuzumab, RO7030816, BTCT4465A, Lunsumio, glofitamab, CD20 TCB, RO7082859, obinutuzumab, Gazyva, Gazyvaro, RO5072759, huMAb , GA101
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
12/24
12/25
NCT05336812: Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Recruiting
2
52
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
Ohio State University Comprehensive Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/24
NCT03824483: Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Recruiting
2
230
US
Zanubrutinib, Obinutuzumab, GA101, Venetoclax, ABT-199
Memorial Sloan Kettering Cancer Center, BeiGene USA, Inc., Roche-Genentech, Massachusetts General Hospital
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL)
02/25
02/25
NCT04722172: A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

Active, not recruiting
2
55
US
Acalabrutinib, Obinutuzumab
Memorial Sloan Kettering Cancer Center, AstraZeneca, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
02/25
02/25
ReVenG, NCT04895436 / 2021-001037-39: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Recruiting
2
75
Europe, US, RoW
Venetoclax, Venclexta, ABT-199, GDC-0199, Obinutuzumab, GA101, Gazyva
AbbVie, F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute
Chronic Lymphocytic Leukemia (CLL)
02/25
01/29
CWCLL-001, NCT05322733: Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

Recruiting
2
25
RoW
Orelabrutinib, ICP-022, Obinutuzumab, GA101, Fludarabine, Fludara, Cyclophosphamide
The First Affiliated Hospital with Nanjing Medical University
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
02/25
11/25
NCT02846623: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

Recruiting
2
65
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
02/25
02/25
NCT04560322: Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Recruiting
2
40
US
Venetoclax, Venclexta, Obinutuzumab, Gazyva, Acalabrutinib, Calquence
Massachusetts General Hospital, Genentech, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
NCT03516617: Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
120
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Laboratory Biomarker Analysis, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Patient Observation, Active Surveillance, deferred therapy, expectant management, Observation, Watchful Waiting, Quality-of-Life Assessment, Quality of Life Assessment
Mayo Clinic, National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/26
NCT02629809: Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
2
81
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
03/25
03/25
NCI-2022-07625, NCT05536349: Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
2
60
US
Pirtobrutinib, Obinutuzumab, GA101, Gazyva, RO5072759, Venetoclax, ABT-199, GDC-0199, Valacyclovir, Allopurinol
M.D. Anderson Cancer Center, Loxo Oncology, Inc., The Leukemia and Lymphoma Society
Leukemia
04/25
04/25
FLMRD, NCT04934930: Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status

Recruiting
2
40
RoW
Bendamustin, Ribomustin, Obinutuzumab, Gazyva
Meir Medical Center, Rabin Medical Center, Tel-Aviv Sourasky Medical Center, Assuta Ashdod Hospital, Ziv Medical Center
Follicular Lymphoma
08/25
08/25
NCT05105841: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
2
20
Japan
Venetoclax, Venclexta, ABT-199, GDC-0199, Ibrutinib, Imbruvica, Obinutuzumab, GA101, Gazyva, RO5072759
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/25
10/25
VIS, NCT05478512: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

Recruiting
2
78
Europe
VenObi+Ven or VenObi+VenZan
Gruppo Italiano Malattie EMatologiche dell'Adulto
High Risk CLL, Chronic Lymphocytic Leukemia
05/26
07/27
NCT06108232: Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Recruiting
2
36
US
Obinutuzumab, GA101, Gazyva, RO5072759, CC-99282
M.D. Anderson Cancer Center, Bristol-Myers Squibb
Follicular Lymphoma, Tumor
12/25
12/27
NCT05783596: Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Recruiting
2
50
US
Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Glofitamab, RO7082859
Reid Merryman, MD, Genentech, Inc.
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
01/26
01/29
ChiCTR2300071433: Clinical trial of Zanubrutinib With Obinutuzumab as First-Line Treatment in Older Patients With Mantle Cell Lymphoma

Not yet recruiting
2
48
 
Zanubrutinib with Obinutuzumab
The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University; The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, NA
Mantle Cell Lymphoma
 
 
NCT05846750: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma

Recruiting
2
59
RoW
Obinutuzumab, GA101, lenalidomide
Institute of Hematology & Blood Diseases Hospital
Marginal Zone Lymphoma
05/26
05/28
NCT04447768: The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)

Active, not recruiting
2
100
US
Obinutuzumab, Venetoclax
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Chronic Lymphocytic Leukemia (CLL)
07/26
07/26
NCT04169737: Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting
2
168
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Calquence, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
07/26
07/26
FIGHT, NCT04908228: Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

Recruiting
2
53
Europe
Ibrutinib and obinutuzumab, Imbruvica and Gazyvaro
Paolo Ghia
Chronic Lymphocytic Leukemia
09/26
09/27
NCI-2023-06838, NCT06054776: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recruiting
2
40
US
Acalabrutinib, ACP-196, Bruton Tyrosine Kinase Inhibitor ACP-196, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Glofitamab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody RO7082859, RO 7082859, RO7082859, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
City of Hope Medical Center, National Cancer Institute (NCI)
Mantle Cell Lymphoma
09/26
09/26
BruVenG, NCT05650723: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

Recruiting
2
50
US
Zanubrutinib Pill, Brukinsa, Venetoclax Pill, Venclexta, Obinutuzumab Injection, Gazyva
Weill Medical College of Cornell University, BeiGene, Genentech, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
01/25
12/27
R-Pola-Glo, NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP

Recruiting
2
80
Europe
Glofitamab, Rituximab, Obinutuzumab, Polatuzumab vedotin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Charite University, Berlin, Germany, University of Salzburg, Arbeitsgemeinschaft medikamentoese Tumortherapie, Roche Pharma AG, Zentrum für Klinische Studien Leipzig, Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
09/27
09/28
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
PORTAL, NCT06071871: A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab as a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Not yet recruiting
2
99
NA
Glofitamab, Columvi, Polatuzumab vedotin, Polivy, Obinutuzumab, Gazyvaro
University College, London, Hoffmann-La Roche
Large B-cell Lymphoma
01/27
07/28
 

Download Options